CELLINK announces partnership with AstraZeneca to provide advanced 3D-bioprinted liver organoids

CELLINK, focused on the development and commercialization of innovative bioprinting technologies and bioinks, announced today that the company will collaborate with AstraZeneca to provide advanced 3D-bioprinted liver organoids for drug discovery purposes in cardiovascular, renal and metabolic diseases.

In tissue engineering, the need for assembly of three-dimensional (3D) tissues is important. 3D-bioprinting has emerged as a useful technology to recapitulate the microenvironment of native tissue, allowing for precise printing of multiple cells into a pre-defined position.

CELLINK has an R&D lab in AstraZeneca’s BioVentureHub in Gothenburg, Sweden. The new collaboration will leverage CELLINK’s innovative and patent-pending bioink, Extra Cellular Matrix and Laminin based bioinks, which enables human cells to grow and function as they would in the human body.

Source:

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    CELLINK. (2020, May 15). CELLINK announces partnership with AstraZeneca to provide advanced 3D-bioprinted liver organoids. News-Medical. Retrieved on July 23, 2024 from https://www.news-medical.net/news/20200515/CELLINK-announces-partnership-with-AstraZeneca-to-provide-advanced-3D-bioprinted-liver-organoids.aspx.

  • MLA

    CELLINK. "CELLINK announces partnership with AstraZeneca to provide advanced 3D-bioprinted liver organoids". News-Medical. 23 July 2024. <https://www.news-medical.net/news/20200515/CELLINK-announces-partnership-with-AstraZeneca-to-provide-advanced-3D-bioprinted-liver-organoids.aspx>.

  • Chicago

    CELLINK. "CELLINK announces partnership with AstraZeneca to provide advanced 3D-bioprinted liver organoids". News-Medical. https://www.news-medical.net/news/20200515/CELLINK-announces-partnership-with-AstraZeneca-to-provide-advanced-3D-bioprinted-liver-organoids.aspx. (accessed July 23, 2024).

  • Harvard

    CELLINK. 2020. CELLINK announces partnership with AstraZeneca to provide advanced 3D-bioprinted liver organoids. News-Medical, viewed 23 July 2024, https://www.news-medical.net/news/20200515/CELLINK-announces-partnership-with-AstraZeneca-to-provide-advanced-3D-bioprinted-liver-organoids.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
CELLINK granted U.S. patent for unique cellulose-based bioink technology